Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 16M | 10M | 7M | 7M | 7M |
| Gross Profit | 11M | 7M | 4M | 3M | 3M |
| Operating Income | -42M | -31M | -29M | -32M | -30M |
| EBITDA | -41M | -26M | -27M | -27M | -29M |
| Net Income | 42M | -26M | -29M | -29M | -31M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$6.87
+4.57% today
1Y Change
+11.65%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Profound Medical Corp. (PROF) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $6.87 and up 11.6% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +58.3%, EPS growth of +231.8%, a dividend yield of 0.0%. What stands out right now is revenue +58.3%, EPS +231.8%, free cash flow -128.5% with operating margin -239.5% and ROIC -23.8%. Valuation already assumes a fairly strong business story at price/sales 11.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PROF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PROF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PROF Max Drawdown
-41.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PROF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$6.9M
+2.9% YoY
FY Net Income
-$30.7M
-7.1% YoY
Free Cash Flow
-$23.0M
+11.0% YoY
Revenue Growth
+58.3%
EPS Growth
+231.8%
Gross Margin
70.2%
Net Margin
-248.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 16M | 10M | 7M | 7M | 7M |
| Gross Profit | 11M | 7M | 4M | 3M | 3M |
| Operating Income | -42M | -31M | -29M | -32M | -30M |
| EBITDA | -41M | -26M | -27M | -27M | -29M |
| Net Income | 42M | -26M | -29M | -29M | -31M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 82M | 55M | 26M | 47M | 67M |
| Total Assets | 193M | 70M | 44M | 64M | 87M |
| Total Liabilities | 102M | 10M | 13M | 12M | 6M |
| Shareholder Equity | 91M | 60M | 31M | 52M | 81M |
| Total Debt | 6M | 5M | 8M | 8M | 1M |
| Net Debt | -75M | -50M | -18M | -38M | -66M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22M
+13.3% YoY
Capital Expenditures
593K
Free Cash Flow
23M
+11.0% YoY
Key ratios
Gross Margin
70.2%
Operating Margin
-239.5%
Net Margin
-248.5%
ROE
-85.7%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.